Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies

BACKGROUND: The release of pro-inflammatory cytokines, resulting in cytokine storm syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on res...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaminski, Monica A., Sunny, Subin, Balabayova, Khayala, Kaur, Avneet, Gupta, Aanchal, Abdallah, Marie, Quale, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521212/
https://www.ncbi.nlm.nih.gov/pubmed/33002613
http://dx.doi.org/10.1016/j.ijid.2020.09.1447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521212/
https://www.ncbi.nlm.nih.gov/pubmed/33002613
http://dx.doi.org/10.1016/j.ijid.2020.09.1447

Ejemplares similares